Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the ...

Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

In its most transformative release to date, Calix announces its next-generation cloud-and-agentic enabled Broadband Platform built on Google Cloud’s AI and data infrastructure. This evolution unites ...

Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” ...

Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...

Pennsylvania-based Conestoga Capital Advisors sold 855,435 Vertex shares for an estimated $24.8 million based on average ...

After pioneering haptic gloves for virtual reality, Tokyo-based startup Diver-X is taking aim at one of the most familiar computer tools: the ...

Vertex (VERX) closed the last trading session at $25.86, gaining 3.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...

BioMarin will host a conference call and webcast to discuss third quarter 2025 financial results today, Monday, October 27, 2025, at 4:30 p.m. ET. This event can be accessed through this link or on ...